what is melanotan 2 peptide: Frequently asked questions

Pigmentation persists for 3–4 weeks after the last dose because melanin remains in keratinocytes as they migrate through the epidermis to the stratum corneum. Once receptor stimulation stops, no new melanin is synthesised, and the tan fades at the rate of natural epidermal turnover. Approximately 28 days. Maintenance dosing (0.25–0.5mg once or twice weekly) can sustain pigmentation indefinitely without cumulative receptor desensitisation.

Yes, but response varies. Fitzpatrick Type I skin has low constitutive melanin and limited melanocyte density, so Melanotan-2 peptide will produce pigmentation. But the shade achieved will be lighter and develop more slowly than in Type III or IV skin. Expect tan development over 10–14 days rather than 5–7 days. The compound cannot synthesise melanin in melanocytes that don't exist, so individuals with complete albinism (OCA1A, total absence of functional tyrosinase) will not tan regardless of dose.

Nausea is MC4R-mediated and occurs in approximately 30–40% of users during initial doses. It peaks 30–60 minutes post-injection and resolves within 2–4 hours. Mitigation strategies: inject in the evening before sleep (so nausea occurs during rest), reduce dose to 0.1–0.25mg and titrate upward slowly, or take the injection with a small amount of food. The effect diminishes with repeated dosing as receptor adaptation occurs. Most users report nausea resolution by day 5–7 of a loading protocol.

Switch to Melanotan 1 (afamelanotide), which maintains MC1R-selective activity without significant MC4R binding. Melanotan 1 produces equivalent melanogenesis with negligible appetite suppression, erectile effects, or nausea, making it suitable for studies focused exclusively on pigmentation or photoprotection mechanisms. The trade-off is a shorter half-life requiring more frequent administration or continuous infusion to maintain receptor occupancy.

Refrigerate immediately and do not use if the vial was at room temperature for more than 12 hours. Peptide bonds and the lactam bridge structure undergo accelerated hydrolysis at temperatures above 8°C, and while the solution may appear unchanged, receptor binding affinity can decrease by 20–40% after prolonged ambient exposure. Studies on peptide stability show that cyclic peptides are particularly vulnerable to conformational shifts when thermal energy disrupts the constrained ring structure.

Nausea results from MC4R activation in the hypothalamus and area postrema. The chemoreceptor trigger zone in the brainstem. And typically resolves within 2–4 hours. Reducing the initial dose to 0.25 mg and administering in the evening before sleep allows the acute nausea phase to pass during rest. Gradual dose escalation over 7–10 days permits receptor desensitization and reduces the incidence of gastrointestinal side effects in subsequent doses.

Verify injection technique, reconstitution sterility, and peptide storage conditions before assuming the compound is inactive. Individuals with Fitzpatrick skin type I and minimal baseline melanocyte activity may require 10–14 days to produce visible pigmentation, as tyrosinase upregulation and melanosome maturation follow a lag phase that varies with genetic melanin synthesis capacity. If no pigmentation appears after 14 days of consistent dosing, the peptide may have been denatured during storage or reconstitution, or the individual may have MC1R polymorphisms that reduce receptor responsiveness.